LGALS3 and neoplasm: To determine whether this inhibition of the compounds on tumour cell adhesion was related to inhibition of the galectin-3-mediated actions, expression of galectin-3 in these cells were either knocked out by CRISPR/Cas9 (MDA-MB-231 and PANC-1) or knock-down (SW620) by shRNA.